PPARγ can be considered a valid therapeutic target in the treatment of various cancers, including AML; in particular, it has been shown that stimulation with pioglitazone, a PPARg agonist, could be highly effective for patients with non-M3 AML [21]. Here, PPARG is linked to cancer.